Cytek Biosciences, Inc. (CTKB)
NASDAQ · Healthcare
Cytek Biosciences, Inc. Shareholder Equity 2020–2025
Cytek Biosciences, Inc. annual/quarterly shareholder equity history from 2020 to 2025. Shareholder equity represents the net worth of a company, calculated as total assets minus total liabilities.
- Cytek Biosciences, Inc. shareholder equity for the quarter ending December 31, 2025 were 341.7M, a 13.64% decrease year-over-year.
- Cytek Biosciences, Inc. shareholder equity for 2025 were 341.7M, a 13.64% decrease from 2024.
- Cytek Biosciences, Inc. shareholder equity for 2024 were 395.7M, a 0.68% increase from 2023.
- Cytek Biosciences, Inc. shareholder equity for 2023 were 393.1M, a 7.63% decrease from 2022.
- Cytek Biosciences, Inc. shareholder equity for 2022 were 425.5M.
Shareholder Equity
QUARTERLY · $B
YOY QUARTERLY GROWTH · %
| Cytek Biosciences, Inc. Annual Shareholder Equity (Millions of US $) | |
|---|---|
| 2025 | $342 |
| 2024 | $396 |
| 2023 | $393 |
| 2022 | $426 |
| 2021 | $405 |
| 2020 | $-16 |
| Cytek Biosciences, Inc. Quarterly Shareholder Equity (Millions of US $) | |
|---|---|
| 2025-12-31 | $342 |
| 2024-12-31 | $396 |
| 2023-12-31 | $393 |
| 2022-12-31 | $426 |
| 2021-12-31 | $405 |
| 2020-12-31 | $-16 |
Cytek Biosciences, Inc. Shareholder Equity — FAQ
Cytek Biosciences, Inc. (CTKB) shareholder equity over the last 6 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see CTKB's shareholder equity history?
The chart and table above show Cytek Biosciences, Inc.'s shareholder equity by year and by quarter, including the growth rate.